Dr Freitag obtained his medical degree from Kiel University, Germany in 1994. He started his career in the pharmaceutical industry at Roche in pharmacovigilance and medical affairs. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, finally as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to head up Vascular Medicine and moved on to become responsible for global clinical development across the portfolio. He joined Debiopharm International SA in 2016 to lead the clinical R&D function managing international drug development across Phase I to III. Recently, he joined Dynacure as Chief Medical Officer where he is responsible for medical and regulatory strategy, including clinical development of the lead compound in CNM.
PLEASE DONATECLICK HERE
NEWS & UPDATES
- Batmen and Robin Triumph In The 100K Ultra Challenge from London to BrightonJune 12, 2019Massive congratulations and thanks to university friends, Phil Brunetti, Craig Strachan and Naeem Ghulamali who recently walked the 100km Ultra […]
- Joint research call with the world renowned Great Ormond Street Hospital Charity, and SparksJune 3, 2019Great Ormond Street Hospital Charity and Sparks have announced a national funding call in child health research in 2019/20. Under this funding call […]
- Another innovative approach to treatment for centronuclear and myotubular myopathy from the laboratory of Jocelyn Laporte at IGBMCMay 16, 2019In this study, the researchers found that increasing the level of BIN1 (Amphiphysin 2) rescues myotubular myopathy resulting from a MTM1 defect, in […]
- Jennie’s First MarathonMay 14, 2019Massive congratulations to our long term supporter, Jennie May, who completed the Milton Keynes marathon on 6th May. Jennie ran the marathon, her […]
- Audentes Therapeutics presents the latest positive data from ASPIRO, their gene therapy clinical trial for x-linked myotubular myopathyMay 7, 2019Today, 1st May, at a meeting of the American Society of Gene and Cell Therapy, Audentes announced new positive data from ASPIRO their Phase1/2 […]